Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: Free Radic Biol Med. 2014 Jan 17;70:155–166. doi: 10.1016/j.freeradbiomed.2014.01.015

Figure 8.

Figure 8

Nrf2-knockdown magnifies the increase in C3a and C3b activation products after CSE. Cells transfected with 15nM non-targeting siRNA control (CTRL) or siRNA Nrf2 were treated with DMSO vehicle control or CSE. A) Graph showing no C3a generation after 25μg/ml CSE alone, but an increase in C3a, as measured by ELISA, when combined with Nrf2-KD. B) Graph showing C3a generation after 125μg/ml CSE alone, which is magnified when combined with Nrf2-KD. C. Representative immunoblot of C3b after treatment with 125μg/ml CSE or vehicle control with siRNA CTRL or siRNA Nrf2. GAPDH was used as a loading control. D. Graph of increased C3b after 125μg/ml CSE and Nrf2-KD over CSE alone. E. Representative immunoblot of iC3b after treatment with either siRNA CTLR or Nrf2 siRNA, and then DMSO vehicle control or 125μg/ml CSE for 24h. Recombinant iC3b (2ng) served as a positive control. GAPDH was used as a loading control. *p<0.05. For all assays, n=3 ind exp.

HHS Vulnerability Disclosure